 IRVINE, CA ACCESSWIRE May 12, 2020 Hancock Jaffe Laboratories, Inc. HJLI, a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received approval from the Superintendent of Health of the National Health Counsel for the Republic of Paraguay to conduct a first-in-human study for its CoreoGraft bioprosthetic graft. The first-in-human study will initially consist of five patients who will receive CoreoGrafts as part of their coronary artery bypass graft CABG surgeries. The CoreoGraft patients will be monitored for a one-year period post CoreoGraft surgery, with interim results reported at 30, 90, 180, and 365 days. 